NKTR - Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PR Newswire
SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2 nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time .
The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . This webcast will be available for replay until April 28, 2024 .
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin ( REZPEG , or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata . Other pipeline programs include two preclinical candidates, a PEG-colony stimulating factor protein engineered to selectively modulate resolution processes of inflammation and NKTR-0165, a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar , together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
SOURCE Nektar Therapeutics
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.